An open-label nonrandomized study of 26 patients with BRAF V600–mutant LCH and Erdheim-Chester disease indicated that vemurafenib had prolonged efficacy, with a 62% confirmed overall response rate (45). This evidence concerns the gene BRAF and Erdheim-Chester disease.